

## AGM Chairman's address and CEO's presentation

**Melbourne, Australia; 20 November 2020:** Attached is the Chairman's address together with the CEO's presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

The AGM will be held online. Shareholders and proxyholders will be able to listen, view presentations, vote and ask questions during the meeting in real-time through the Lumi virtual platform, for which details are available via <https://starpharma.com/2020agm>.

---

### About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships.

**VivaGel®:** Starpharma's women's health product - VivaGel® BV is based on SPL7013, astodimer sodium, a proprietary dendrimer. VivaGel® BV for bacterial vaginosis (BV), is available for sale under the brand names Betafem® BV Gel (UK), Betadine BV™ (Europe), Betadine™ BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand) and a new drug application has been submitted to the US FDA. Starpharma has licensed the sales and marketing of VivaGel® BV to ITF Pharma for the US; Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel® condom (an antiviral condom which includes VivaGel® in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel® condom has been launched in Japan under Okamoto's 003 brand, and in Australia and Canada under the LifeStyles Dual Protect® brand. The VivaGel® condom is approved in Europe.

**DEP® - Dendrimer Enhanced Product®:** Starpharma's DEP® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP® programs, including improved efficacy, safety and survival. Starpharma has three internal DEP® products – DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan - in clinical development in patients with solid tumours. Starpharma's partnered DEP® programs include a multiproduct DEP® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more. In June 2019 Starpharma signed a Development and Option agreement with AstraZeneca for a DEP® version of one of AstraZeneca's major marketed oncology medicines.

[Starpharma.com](http://Starpharma.com) | [Twitter](https://twitter.com/starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

---

### Media:

**WE Communications**  
Rebecca Wilson  
Mob: +61 417 382 391  
[rwilson@we-worldwide.com](mailto:rwilson@we-worldwide.com)

Arthur Chan  
+61 2 9237 2805  
[arthurc@we-worldwide.com](mailto:arthurc@we-worldwide.com)

### Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704

[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)

4-6 Southampton Crescent  
Abbotsford Vic 3067

### Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.



**Chairman's Address**  
**Starpharma Holdings Limited**  
**Annual General Meeting**  
**20 November 2020**

On behalf of your Board of Directors, I welcome you to Starpharma's 2020 Annual General Meeting, which is our first virtual AGM.

The COVID-19 pandemic has had such a disruptive impact on our lives and the economy. I sincerely hope that you and your loved ones have remained safe and healthy throughout the year. During this time, Starpharma's Senior Executives and Board have responded proactively, employing a comprehensive set of measures to ensure the safety of our staff and trial participants, while also minimising disruption to our business, including the continued operations of our laboratories in Melbourne. It has taken a significant coordinated commitment from management and all of our staff to achieve this, especially in Victoria, and we commend our staff for their diligence and professional response in a rapidly evolving and uncertain environment. I am pleased to say that we have been able to achieve this, whilst still maintaining our focus on our strategic priorities despite the extraordinary challenges presented by the pandemic.

The strategic focus of Starpharma over many years has been to leverage our proprietary dendrimer technology to build a stable of high-value products and partnerships that address significant unmet patient need for the betterment of the community and our shareholders.

This year, in a year like no other, we did exactly that.

Those of you familiar with our business will know that our proprietary dendrimer SPL7013, which is the active component in our VivaGel® products, is a broad spectrum antiviral and has significant antiviral activity against a range of viruses. With the advent of the coronavirus pandemic, we quickly moved to test SPL7013 and found it to be virucidal, inactivating more than 99.99% of the coronavirus that causes COVID-19.

With this data in hand, Starpharma's team worked rapidly to identify a highly novel and valuable product opportunity and since then has worked tirelessly to expedite the development and commercialisation of our product VIRALEZE, a preventative COVID nasal spray which incorporates our broad spectrum antiviral SPL7013. SPL7013 is the active in other Starpharma products which are already approved in 40 countries and on market in the UK, Europe, Asia, Australia and New Zealand. VIRALEZE is designed to be an additional line of defence against COVID-19, alongside PPE and any potential vaccine, for use by the general population, and workplaces including those in the frontline of this crisis. As we have learnt in 2020, there is still some uncertainty around the availability of an effective vaccine that can minimise the human and economic impact of this pandemic.

I think VIRALEZE and its evolution and fast-tracked development is a perfect illustration of the Company's ability to rapidly innovate and leverage its dendrimer technology to create additional valuable opportunities for the health of people globally, as well as our shareholders.

Notwithstanding the challenges of the pandemic and the rapid development of our nasal spray, Starpharma continued to expand the global footprint for VivaGel BV® with further launches in additional countries in Europe and Asia and further approvals in new regions



such as Africa and the Middle East. While the pandemic has caused some disruption to launches, and lockdowns have had some impact on consumer demand, our global expansion for VivaGel® BV continues, and it has been very pleasing to receive so many positive product reviews by new customers and healthcare professionals.

Given the typical development timeframes for new medical products, it has been a privilege to see an Australian innovation, VivaGel® BV, fully commercialised during my tenure, and now with another novel product expected to be in market next year.

Starpharma has also built strong and lasting partnerships, which are a critical feature to bringing medical innovations and breakthroughs to patients in need.

It has been really exciting to see AstraZeneca advance its novel anti-cancer drug AZD0466 into human trials in the US this year. This product is of high priority for AstraZeneca and continues to attract significant interest from clinicians. We look forward further updates as the trial progresses.

The partnerships we have executed with our DEP® platform have the potential to create life changing products for patients, and long-term revenues for Starpharma by way of milestones and royalties. Because the DEP® platform can be licensed to multiple partners, and be applied to multiple products in parallel, it creates exceptional optionality. While a number of our partnerships must remain confidential at this stage, we were able to share the signing of a new partnership this year, with Chase Sun, for a novel anti-infective DEP® program. Partnering in this new therapeutic area illustrates the versatility and broad applicability of DEP®.

Our DEP® technology has been used to improve the performance of, and reduce the side effects of many oncology drugs, and this year we also expanded its use to create DEP® versions of other non-oncology drugs, including anti-infectives, and most recently the antiviral drug, remdesivir. Gilead's remdesivir is proving to be a critically important antiviral drug which was recently approved by the FDA for the treatment of COVID-19 patients. In its current form, this drug needs to be administered as an intravenous infusion in hospital, which can take more than 2 hours. Starpharma has developed a long-acting DEP® version of remdesivir, which potentially could be administered subcutaneously, in 2-3mls. This potentially expands the usage of this product into non-hospital settings, such as aged care.

This program illustrates the Company's capacity to rapidly turnaround new DEP® candidates with compelling benefits for patients and commercial partners.

Alongside our partnered DEP® programs, we have made significant progress with our internally developed DEP® products. We now have three clinical stage DEP® assets in phase 2, for which we have reported positive patient outcomes across a range of tumours. We are thrilled that multiple patients have also experienced benefits such as tumour shrinkage and prolonged periods of stable disease. In addition to AZD0466, the results from Starpharma's three phase 2 trials will be important milestones for the Company and will support new DEP® licences.

To ensure that we are in the best position to accelerate the development of these important DEP® products, their commercialisation and others, Starpharma recently completed an oversubscribed capital raising and is now in an extremely strong financial position. These funds will also enable the Company to accelerate the development and commercialisation activities for the launch of the VIRALEZE, as well as expedite the pipeline development of new DEP® candidates. On behalf of the Board, I thank all the investors and shareholders who participated in the Share Purchase Plan and placement.



When I reflect on Starpharma's recent progress, for such a small company, it is truly remarkable what has been achieved. We licensed VivaGel® BV in more than 160 countries around the world and then launched this important women's health product in the UK, Europe, Asia, Australia and New Zealand. We partnered with

AstraZeneca to develop a DEP® improved version of one of their major drugs and progressed a novel AstraZeneca DEP® product into the clinic. We also advanced two further DEP® products within our own portfolio, whereby we now have three clinical stage DEP® assets, and a deep pipeline which includes exciting programs in Antibody Drug Conjugates and radiotherapeutics. And most recently, we developed the SPL7013 COVID-19 nasal spray, which could prove to be a hugely important product, as COVID numbers continue to surge in the Northern hemisphere.

I think this quantum of achievement of our team of around 45 staff speaks to the innovation and drive embedded in the culture at Starpharma. On behalf of the Board I thank all our staff for their hard work and determination over this period and Jackie and her management team for their strong and clear leadership.

I also thank my fellow board members. This year we welcome David McIntyre to his first AGM for Starpharma. David has been a fantastic addition to the Board. We also say farewell to Dick Hazleton, who retires at the end of this meeting. Dick has made an invaluable contribution to the Company during his tenure and we sincerely thank him for his commitment and wise counsel.

As we look to the future, I am enormously proud to be part of Starpharma and am excited for the key inflection points in the period ahead. In 2021 we expect to have the nasal spray ready for market in the first half of calendar year, and will see further approvals and launches of VivaGel® BV, as well as the expansion and completion of some of our phase 2 DEP® trials, and we expect to sign further DEP® partnerships with leading pharmaceutical companies.

With each passing quarter, the progression of our strategy reinforces our long term growth prospects and our potential to deliver excellent returns to shareholders. We are really well funded, we have globally leading platform technology and potentially our strategies can deliver very substantial future royalty flows.

I thank shareholders for their support, and look forward to the year ahead.

Thank you

Rob Thomas AO Chairman